52 wk: 0.01-0.12
current: 0.076
PDUFA Date: 10/15/09
"The analyst, Carrie Snyder, places a target price on the shares of between $0.30 and $0.50, should expected FDA clearances be granted" (BH)
ACOR: Acorda Therapeutics http://finance.yahoo.com/q?s=acor
52 week: 14.42- 29.27
current: 23.77
FDA advisory committee meeting: 10-14-09
PDUFA: 10-22-09
Thoughts: Worth taking a chance on and I might consider buying a few shares at these low prices: Another analysts positive views:
ReplyDeletehttp://seekingalpha.com/instablog/424698-m-e-garza/13391-bioelectronics-corporation-otc-biel-poised-for-major-revenue-growth